Publications Sci Rep Jul 10;7 1 Revealing enterovirus infection in chronic human disorders: An integrated diagnostic approach. The program also aims to analyze results of clinical trials of new vaccines, including studies in special populations, such as premature infants. Cancer Res Nov 15;65 22 Some oral poliovirus vaccines were contaminated with infectious SV40 after The design and manufacturing of vaccines is done mainly by the vaccine industry, and to a lesser extent by academic researchers. J Virol Methods Apr; Deep sequencing approach for genetic stability evaluation of influenza A viruses. Science Jan 22; Eradicating polio: a balancing act. Specifically, we use transgenic mice susceptible to poliomyelitis to compare the efficacy of different products containing inactivated poliovirus vaccine. Clin Vaccine Immunol Aug;18 8 Immunogenicity of inactivated polio vaccine with concurrent antiviral V administration in mice. Database Mar 17;baw High-performance integrated virtual environment HIVE : a robust infrastructure for next-generation sequence data analysis. Antiviral Res May 10; Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains.
Konstantin Chumakov, ASSOCIATE DIRECTOR FOR RESE, works for the FDA.
Call Email inside. First, we monitor the genetic stability of live viral vaccines through sensitive analysis of their genetic composition. Specifically, we use transgenic mice susceptible to poliomyelitis to compare the efficacy of different products containing inactivated poliovirus vaccine. Konstantin Chumakov, Ph.D. .
We have (H1N1)pdm09s in orange and the H3N2s in red. . In orange are influenza B viruses.
J Infect Dis Jun 15; 12 Comparison of the immunogenicity of various inactivated polio vaccine booster doses by intradermal versus intramuscular routes in HIV-infected adults. We are also trying to incorporate new imaging techniques and other technologies to study the effect of vaccines on these mice.
OPV can trigger emergence of circulating vaccine-derived polioviruses cVDPV and can also establish persistent infections in immunocompromised individuals who subsequently excrete vaccine derived viruses VDPV. Neverov A, Chumakov K. Sci Rep Jul 10;7 1 Revealing enterovirus infection in chronic human disorders: An integrated diagnostic approach. J Virol Oct 1;88 19 New small-molecule inhibitors effectively blocking picornavirus replication.
J Clin Microbiol Jun;43 6 Genomic analysis of vaccine-derived poliovirus strains in stool specimens by combination of full-length PCR and oligonucleotide microarray hybridization.
Finite dimensional linear systems pdf viewer
|Antiviral Res May 10; Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains.
Proc Natl Acad Sci U S A Nov 16; 46 Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccines.
The program is pursuing several strategies to achieve this goal: 1 analyzing how likely it is that vaccines made from live viruses will undergo gene mutations that degrade their safety and effectiveness; 2 determining which molecular parts of the vaccines are responsible for triggering immune system responses and studying in detail those immune system responses; and 3 creating new ways to evaluate both the inactive components of vaccines used to increase vaccine potency e.
J Clin Virol Apr; A single chimpanzee-human neutralizing monoclonal antibody provides post-exposure protection against type 1 and type 2 polioviruses. Sci Rep Jul 10;7 1 Revealing enterovirus infection in chronic human disorders: An integrated diagnostic approach.
Evaluation of Safety and Potency of Viral Vaccines Based on Analysis of Molecular Consistency FDA
Alexander Neverov and Konstantin Chumakov. by colored bars: mutations to A shown in orange, mutations to C in red, mutations to G in blue, and mutations to U in green. . E-mail: [email protected] and. Konstantin M Chumakov CBER/FDA Loading buffer: 10x Bromophenol blue or equivalent (eg 10x Orange Gel Loading dye (Licor # ).
Using this approach, FDA regulators will work to ensure that vaccines conform to the highest standards of quality, based on their molecular consistency.
Antivir Ther ;16 7 Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V Expert Rev Vaccines Jul;8 7 Future of polio vaccines. This includes creating ways to determine the repertoire of epitopes epitope profiles that inactivated vaccines contain, and analyzing the repertoire of antibodies paratope profiles in sera of vaccine recipients. PLoS One Feb 10;11 2 :e Fluorescence adherence inhibition assay: a novel functional assessment of blocking virus attachment by vaccine-induced antibodies.
This will maximize the efficiency of these efforts and thus facilitate FDA regulatory evaluation of these products, reducing the time needed to approve vaccines and make them available to the public.
Video: Konstantin chumakov fda orange Orange Digital LAB
1 (T.Z.); [email protected] (S.P.); (V.I.A.); [email protected] (K.C.); . derived from these serotypes are depicted in red, orange, and green respectively. Zhaochun Chen, Konstantin Chumakov, Eugenia Dragunsky, Diana. same as in panel A. Antigenic sites 1 and 2 are shown in red and orange, respectively.
Konstantin Chumakov. cEV11 of genogroup A are shown in orange, while genogroups B, C, D in purple, blue, and green, respectively.
J Med Virol Oct;78 10 Microarray assay for detection and discrimination of Orthopoxvirus species. We are also trying to incorporate new imaging techniques and other technologies to study the effect of vaccines on these mice.
Video: Konstantin chumakov fda orange oranges
Expert Rev Vaccines Jul;8 7 Future of polio vaccines. Scientific Overview We are analyzing the molecular consistency of vaccines in a variety of ways.
J Infect Dis May 15; 10 Analysis of reversions in the 5'-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines.
Sp sp2 sp3 hybridization pdf to jpg
|Neverov A, Chumakov K.
In addition, our program is studying certain adverse reactions caused by oral polio vaccine OPV that require treatment. J Infect Dis Aug; 4 Vaccine poliovirus shedding and immune response to oral polio vaccine in HIV-infected and -uninfected Zimbabwean infants. Blood Coagul Fibrinolysis Sep;19 6 Interaction of coagulation factor VIII with members of the low-density lipoprotein receptor family follows common mechanism and involves consensus residues within the A2 binding site Antiviral Res May 10; Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains.